| Type | Title | Date Released | |
|---|---|---|---|
SCHEDULE 13G | Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Filed by) New | ||
8-K | Hengrui Pharma and Braveheart Bio Present Positive 52-Week Phase 2 Data for HRS/BHB-1893 in Obstructive Hypertrophic Cardiomyopathy at AHA 2026 | ||
SCHEDULE 13G | FMR LLC (Filed by) | ||
SCHEDULE 13D/A | ORBIMED ADVISORS LLC (Filed by) | ||
10-Q | Form 10-Q | ||
8-K | Braveheart Bio Reports Second Quarter 2026 Financial Results and Provides Business Update | ||
SCHEDULE 13D | ORBIMED ADVISORS LLC (Filed by) | ||
3 | Agarwala Vineeta (Reporting) | ||
SCHEDULE 13D | AH Bio Fund IV, L.P. (Filed by) | ||
SCHEDULE 13G | Frazier Life Sciences Public Fund, L.P. (Filed by) | ||
4 | Andreessen Marc L (Reporting) | ||
4 | Chimovits Erez (Reporting) |
